AV
ArriVent BioPharma, Inc.
AVBP · NASDAQ
$30.10 +0.53% (+$0.16)
1M -3.34%
Market Cap $1.40B
P/E Ratio -
Div. Yield -
ROE 50.26%
Piotroski F-Score Weak
2/9Valuation
53 /100
Fair P/B 3.82x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 20.76%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
0 /100
Poor ROIC 47.92%
ROE 50.26%
Asset turnover 0.00x
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 14.16x
Int. coverage N/A
Stability
38 /100
Moderate Beta 1.36x
EPS volatility 40.17%
Profitable years 0
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o AVBP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Zhengbin Yao
Employees
77
Headquarters
Newtown Square
Nadchodzące wydarzenia
16 LIS
Earnings
Upcoming earnings report